Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

• 收藏
• 分享

专利权人:

发明人:

Ningshu Liu,Katja Haike,Juliane Paul,Antje Margret Wengner

申请号：

US14781224

公开号：

US09999623B2

申请日:

2014.04.04

申请国别(地区):

US

年份:

2018

代理人:

摘要：

Described herein arc methods of treating non-Hodgkins lymphoma (NHL), wherein the non-Hodgkins lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkins lymphoma (NHL) follicular lymphoma (FL) chronic lymphocytic leukemia (CLL) marginal zone lymphoma (MZL) diffuse large B-cell lymphoma (DLBCL) mantle cell lymphoma (MCL) transformed lymphoma (TL) and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/